(VIANEWS) - SEADRILL (SDRL.OL), MELHUS SPAREBANK (MELG.OL), VISTIN PHARMA (VISTN.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SEADRILL (SDRL.OL)
55% sales growth and 8.93% return on equity
Seadrill Limited provides offshore contract drilling services to the oil and gas industry worldwide. It operates in three segments: Harsh Environment, Floaters, and Jack-ups Rigs. The company owns and operates drill ships, semi-submersible rigs, and jack-up rigs for operations in shallow and ultra-deep-water in benign and harsh environments. It serves oil super-majors, state-owned national oil companies, and independent oil and gas companies. Seadrill Limited was formerly known as Seadrill 2021 Limited. The company was incorporated in 2005 and is headquartered in Hamilton, Bermuda.
Earnings Per Share
As for profitability, SEADRILL has a trailing twelve months EPS of kr646.96.
PE Ratio
SEADRILL has a trailing twelve months price to earnings ratio of 0.72. Meaning, the purchaser of the share is investing kr0.72 for every norwegian krone of annual earnings.
Return on Equity
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.93%.
Moving Average
SEADRILL's value is higher than its 50-day moving average of kr462.74 and above its 200-day moving average of kr443.20.Growth Estimates Quarters
The company's growth estimates for the present quarter is 253% and a drop 26.8% for the next.More news about SEADRILL.
2. MELHUS SPAREBANK (MELG.OL)
15.6% sales growth and 10.56% return on equity
Melhus Sparebank, a savings bank, provides various banking products and services to companies, agriculture customers, and private individuals in Norway. The company offers savings accounts; construction and business loans; bank guarantee, overdraft, and leasing services; and credit and bank cards. It also provides various insurance products for liability, health, personnel, occupational injury, travel, accident, business, store, data attack, property damage, craftsman, homeowners, office, vehicle, and farms; savings and pension products; payment services; and online and mobile banking services. The company operates through branch offices in central Trondheim, Heimdal, Ler, and Korsvegen. Melhus Sparebank was founded in 1840 and is headquartered in Melhus, Norway.
Earnings Per Share
As for profitability, MELHUS SPAREBANK has a trailing twelve months EPS of kr17.11.
PE Ratio
MELHUS SPAREBANK has a trailing twelve months price to earnings ratio of 9.29. Meaning, the purchaser of the share is investing kr9.29 for every norwegian krone of annual earnings.
Return on Equity
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.56%.
Yearly Top and Bottom Value
MELHUS SPAREBANK's stock is valued at kr159.00 at 11:20 EST, way under its 52-week high of kr177.00 and higher than its 52-week low of kr151.00.
Volume
Today's last reported volume for MELHUS SPAREBANK is 103 which is 74.12% below its average volume of 398.
Growth Estimates Quarters
The company's growth estimates for the ongoing quarter and the next is 40.1% and 18.8%, respectively.More news about MELHUS SPAREBANK.
3. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 16.03% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 21.9. Meaning, the purchaser of the share is investing kr21.9 for every norwegian krone of annual earnings.
Return on Equity
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.03%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
VISTIN PHARMA's EBITDA is 2.33.
More news about VISTIN PHARMA.